Anup Kasi, Jose Luis Iglesias. "Interim open-label phase 1 results of misetionamide (GP-2250): A small molecule antineoplastic targeting three major transcription factors.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.4177